Bazedoxifene Acetate Polymorph Form A Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new or purer polymorphic forms of existing drug molecules to improve drug formulations, such as bazedoxifene acetate, to enhance bioavailability and stability, as existing forms may vary in ease of preparation, stability, solubility, and pharmacokinetics.
Innovation Solution
A crystalline polymorph (form A) of bazedoxifene acetate is characterized and prepared through specific methods involving hydrogenation and acetic acid treatment, which can be identified by powder X-ray diffraction, IR, and DSC data, offering higher solubility and distinct physical properties compared to form B.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a crystalline polymorph form of bazedoxifene acetate is used, then solubility and bioavailability are improved, but preparation complexity and characterization difficulty increase
Solution Approach 1:
The patent applies parameter changes by modifying crystallization conditions including temperature ranges (0-25°C), solvent compositions (aqueous buffers with organic co-solvents like ethanol or isopropanol), and pH levels to transform bazedoxifene acetate from less soluble polymorph forms to the more soluble form A. This resolves the contradiction by achieving improved solubility and bioavailability through controlled parameter adjustments during crystallization.
Solution Approach 2:
The patent employs preliminary action by pre-characterizing the polymorph forms using multiple analytical techniques (X-ray diffraction, DSC, IR spectroscopy, NMR) before selecting form A for development. This preliminary characterization work, though complex, is performed upfront to establish the unique identification parameters and physical properties of form A, thereby enabling its use to improve solubility and bioavailability while having the complexity already resolved in the characterization phase.
2Stability of the object's composition
If a new polymorphic form is developed, then stability and formulation performance are improved, but manufacturing precision and characterization requirements increase
Solution Approach 1:
The patent uses parameter changes to achieve improved storage stability by optimizing crystallization parameters including temperature (0-25°C), pH (adjusted using buffers like phosphate or acetate), and solvent composition ratios. These parameter optimizations produce form A with enhanced stability while the same parameter controls enable precise manufacturing by defining specific operating windows that favor form A formation.
Solution Approach 2:
The patent applies feedback through comprehensive characterization using X-ray diffraction, DSC, IR spectroscopy, and NMR to monitor and confirm the formation of polymorph form A during development and manufacturing. This feedback mechanism ensures manufacturing precision by providing multiple analytical checkpoints to verify that the desired polymorph is formed, thereby resolving the contradiction between improved stability and manufacturing precision requirements.
3Reliability
If polymorph form A is used, then solubility and bioavailability are enhanced, but ease of manufacture compared to form B decreases
Solution Approach 1:
The patent applies parameter changes by defining specific crystallization conditions including temperature ranges (0-25°C), solvent systems (aqueous buffers combined with organic co-solvents), and pH levels that favor the formation of polymorph form A. These parameter specifications, while requiring precise control, enable enhanced bioavailability through improved solubility, thereby resolving the contradiction between improved performance and ease of manufacture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline polymorph form A of bazedoxifene acetate demonstrates improved solubility and stability, facilitating better biological absorption and formulation, making it suitable for treating conditions related to estrogen deficiency or excess, including bone loss and cholesterol lowering.
Implementation Method 1
reacting hexamethyleneimino benzyloxyindole with a hydrogenating reagent in a solvent and optionally in the presence of a hydrogenation catalyst for a time and under conditions suitable for forming a reaction mixture comprising bazedoxifene free base
Implementation Method 2
treating the reaction mixture with acetic acid for a time and under conditions suitable for forming bazedoxifene acetate polymorphic form A
Implementation Method 3
characterized according to the powder X-ray diffraction data
Implementation Method 4
identified by powder X-ray diffraction
Implementation Method 5
characterized according to the powder X-ray diffraction data, IR data, and DSC data provided herein
Data Source
AI summary
The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof.